PL2601970T3 - Preparaty szczepionki przeciw norowirusowi - Google Patents

Preparaty szczepionki przeciw norowirusowi

Info

Publication number
PL2601970T3
PL2601970T3 PL13157573T PL13157573T PL2601970T3 PL 2601970 T3 PL2601970 T3 PL 2601970T3 PL 13157573 T PL13157573 T PL 13157573T PL 13157573 T PL13157573 T PL 13157573T PL 2601970 T3 PL2601970 T3 PL 2601970T3
Authority
PL
Poland
Prior art keywords
vaccine formulations
norovirus vaccine
norovirus
formulations
vaccine
Prior art date
Application number
PL13157573T
Other languages
English (en)
Inventor
Charles Richardson
Thomas S. Vedvick
Thomas R. Foubert
William T. Tino
Original Assignee
Takeda Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2601970(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines, Inc. filed Critical Takeda Vaccines, Inc.
Publication of PL2601970T3 publication Critical patent/PL2601970T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PL13157573T 2006-09-29 2007-09-28 Preparaty szczepionki przeciw norowirusowi PL2601970T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84791206P 2006-09-29 2006-09-29
US97339207P 2007-09-18 2007-09-18
EP13157573.0A EP2601970B1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Publications (1)

Publication Number Publication Date
PL2601970T3 true PL2601970T3 (pl) 2017-07-31

Family

ID=39268804

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13157573T PL2601970T3 (pl) 2006-09-29 2007-09-28 Preparaty szczepionki przeciw norowirusowi
PL13157572.2T PL2601969T3 (pl) 2006-09-29 2007-09-28 Preparaty szczepionki przeciw norowirusowi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13157572.2T PL2601969T3 (pl) 2006-09-29 2007-09-28 Preparaty szczepionki przeciw norowirusowi

Country Status (17)

Country Link
US (8) US7955603B2 (pl)
EP (4) EP2641613A1 (pl)
JP (3) JP5476544B2 (pl)
KR (1) KR101515489B1 (pl)
AU (1) AU2007303608B2 (pl)
CA (1) CA2664157C (pl)
CY (1) CY1118492T1 (pl)
DK (3) DK2066354T3 (pl)
ES (3) ES2577833T3 (pl)
HK (1) HK1184057A1 (pl)
HU (2) HUE028978T2 (pl)
LT (1) LT2601970T (pl)
PL (2) PL2601970T3 (pl)
PT (1) PT2601970T (pl)
SG (3) SG10202012986SA (pl)
SI (1) SI2601970T1 (pl)
WO (1) WO2008042789A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641613A1 (en) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
EP2134360B1 (en) 2007-03-14 2015-11-18 Takeda Vaccines, Inc. Virus like particle purification
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン,インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
US20120121710A1 (en) * 2009-03-27 2012-05-17 Arizona Board Of Regents For And On Behalf Of Arizona State University Mucosal Immunization
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
CA2993242C (en) * 2010-04-15 2020-12-15 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
AU2012244074B2 (en) * 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
JP6208659B2 (ja) 2011-07-11 2017-10-04 タケダ ワクチン,インコーポレイテッド 非経口ノロウイルスワクチン製剤
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
CN105051537B (zh) * 2012-12-28 2019-04-12 塞尔雷斯蒂斯有限公司 细胞介导的免疫应答试验
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Umnファーマ ウイルス様粒子の精製方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
CN105358178B (zh) 2013-07-17 2019-05-31 陶氏环球技术有限责任公司 用于施加到粘膜的包含甲基纤维素的组合物
KR102474663B1 (ko) 2013-10-03 2022-12-07 다케다 백신즈 인코포레이티드 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
JP6556632B2 (ja) * 2013-12-16 2019-08-07 武田薬品工業株式会社 マイクロニードル
CN108430502A (zh) * 2015-08-28 2018-08-21 科学生物技术公司 诺瓦克病毒疫苗
KR101915740B1 (ko) * 2016-03-18 2018-11-06 (주)인테라 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
EP3717648A4 (en) 2017-11-30 2021-12-01 Medicago Inc. MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS WITH MODIFIED NOROVIRUS VP1 PROTEINS
EP3752185A1 (en) 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
JP7429684B6 (ja) 2018-07-13 2024-03-15 メディカゴ インコーポレイテッド 改変ノロウイルスvp1タンパク質および改変ノロウイルスvp1タンパク質を含むvlp
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
CA3133030A1 (en) 2019-03-12 2020-09-17 Icon Genetics Gmbh Norovirus-like particles with improved stability
WO2021030582A2 (en) * 2019-08-13 2021-02-18 Altimmune, Inc. Therapeutic agent effectiveness and its route of administration
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) * 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
PT757717E (pt) 1994-05-16 2006-09-29 Merck & Co Inc Vacinas de papilomavirus
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
DE69822452T2 (de) 1997-04-08 2006-04-20 Merck & Co., Inc. Stabilisierte humane papillomaviruszusammensetzungen
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
JP4440471B2 (ja) 1998-08-14 2010-03-24 メルク エンド カムパニー インコーポレーテッド ヒトパピローマウイルスのウイルス様粒子の精製方法
EP1140161B1 (en) 1998-12-17 2006-04-19 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
CA2783140C (en) 1999-06-22 2016-07-26 Japan As Represented By Directors-General National Institute Of Infectious Diseases Srsv detection kit
AU2003217413A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US20040033585A1 (en) 2002-06-07 2004-02-19 Mccormick Alison A. Flexible vaccine assembly and vaccine delivery platform
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
EP1599188A2 (en) 2003-02-20 2005-11-30 Becton, Dickinson and Company POWDER FORMULATIONS OF RECOMBINANT STAPHYLOCOCCAL, ENTEROTOXIN B (<SB>R</SB>SEB) MADE BY ATMOSPHERIC SPRAY-FREEZE DRYING FOR IMPROVED VACCINATION
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
US20050152911A1 (en) * 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
KR101501162B1 (ko) 2004-10-20 2015-03-16 사노피 파스테르 바이오로직스, 엘엘씨 일본 뇌염 바이러스 및 웨스트 나일 바이러스에 대한 백신
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006203985A1 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
AU2006224529B2 (en) 2005-03-18 2012-05-24 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
AU2006309286A1 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP1969001A2 (en) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスgiの高感度検出方法
EP2641613A1 (en) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US8474614B2 (en) * 2007-03-14 2013-07-02 BBY Solutions Protective container for a flat screen monitor
EP2134360B1 (en) 2007-03-14 2015-11-18 Takeda Vaccines, Inc. Virus like particle purification
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン,インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
EP2381959A1 (en) 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
BR112012029912A2 (pt) 2010-05-26 2016-11-16 Selecta Biosciences Inc vácinas de combinação de nanotransportadores sintéticos
JP6208659B2 (ja) 2011-07-11 2017-10-04 タケダ ワクチン,インコーポレイテッド 非経口ノロウイルスワクチン製剤
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات

Also Published As

Publication number Publication date
US9861691B2 (en) 2018-01-09
HK1184057A1 (zh) 2014-01-17
JP6134364B2 (ja) 2017-05-24
EP2601969B1 (en) 2016-03-30
JP2010505766A (ja) 2010-02-25
JP2016020378A (ja) 2016-02-04
US20160008455A1 (en) 2016-01-14
DK2601970T3 (en) 2017-02-06
LT2601970T (lt) 2017-04-25
EP2601969A3 (en) 2013-08-21
KR20090079912A (ko) 2009-07-22
US20140286994A1 (en) 2014-09-25
SG10201502490YA (en) 2015-05-28
SI2601970T1 (sl) 2017-04-26
JP5898133B2 (ja) 2016-04-06
US20190125853A1 (en) 2019-05-02
HUE028978T2 (en) 2017-02-28
CA2664157C (en) 2015-12-01
US10512682B2 (en) 2019-12-24
PL2601969T3 (pl) 2016-10-31
JP2013234188A (ja) 2013-11-21
EP2066354B1 (en) 2013-04-17
DK2601969T3 (en) 2016-04-18
DK2066354T3 (da) 2013-05-27
US20120156243A1 (en) 2012-06-21
EP2601970B1 (en) 2016-10-26
US20130273148A1 (en) 2013-10-17
US7955603B2 (en) 2011-06-07
CA2664157A1 (en) 2008-04-10
JP5476544B2 (ja) 2014-04-23
EP2601970A1 (en) 2013-06-12
US9308249B2 (en) 2016-04-12
US20120093861A1 (en) 2012-04-19
US10010599B2 (en) 2018-07-03
ES2420136T3 (es) 2013-08-22
SG174845A1 (en) 2011-10-28
CY1118492T1 (el) 2017-07-12
AU2007303608A1 (en) 2008-04-10
AU2007303608B2 (en) 2013-05-02
ES2618885T3 (es) 2017-06-22
HUE032422T2 (en) 2017-09-28
WO2008042789A1 (en) 2008-04-10
ES2577833T3 (es) 2016-07-19
US8431116B2 (en) 2013-04-30
US20130273105A1 (en) 2013-10-17
KR101515489B1 (ko) 2015-04-30
PT2601970T (pt) 2017-02-02
SG10202012986SA (en) 2021-01-28
EP2066354A4 (en) 2010-10-20
US9272028B2 (en) 2016-03-01
EP2641613A1 (en) 2013-09-25
EP2601969A2 (en) 2013-06-12
US20080299152A1 (en) 2008-12-04
EP2066354A1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
HK1184057A1 (zh) 諾如病毒疫苗製劑
GB2435419B (en) Formulations
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
GB0607088D0 (en) Vaccine
GB0605780D0 (en) Formulations
ZA200808489B (en) Nicotine-carrier vaccine formulation
GB0618697D0 (en) Formulations
GB0610336D0 (en) Formulations
HK1129836A1 (zh) 疫苗
ZA200901592B (en) Vaccine
GB0718404D0 (en) Formulations
GB0711440D0 (en) Aqueous formulations
GB0625593D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0614476D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0607087D0 (en) Vaccine
GB0608962D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0619821D0 (en) Vaccine
GB0620815D0 (en) Vaccine
GB0620337D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine